Neuroendocrine prostate cancer xenografts with large-celland small-cell features derived froma single patient's tumor: Morphological, immunohistochemical, and gene expression profiles

Prostate

Volumn 71, Issue 8, 2011, Pages 846-856

  Aparicio, Ana ^a   Tzelepi, Vasiliki ^a   Araujo, John C ^a   Guo, Charles C ^a   Liang, Shoudan ^a   Troncoso, Patricia ^a   Logothetis, Christopher J ^a   Navone, Nora M ^a   Maity, Sankar N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Androgen independent; Array; Cancer; Castrate resistant; Neural development

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; RNA;

ADENOCARCINOMA; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PELVIS EXENTERATION; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; SALVAGE THERAPY; SCID MOUSE; SMALL CELL CARCINOMA; TISSUE MICROARRAY; TISSUE SECTION; XENOGRAFT;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SMALL CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, SCID; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953701350     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21301     Document Type: Article

References (33)

1. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 2008;118(8):2697-2710.
2. Clegg N, Ferguson C, True LD, Arnold H, Moorman A, Quinn JE, Vessella RL, Nelson PS. Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 2003;55(1):55-64. (Pubitemid 36397745)
3. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 1987;59(10):1803-1809.
4. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20(14):3072-3080. (Pubitemid 34791096)
5. Turbat-Herrera EA, Herrera GA, Gore I, Lott RL, Grizzle WE, Bonnin JM. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study. Arch Pathol Lab Med 1988;112(11):1100-1105.
6. Tanaka M, Suzuki Y, Takaoka K, Suzuki N, Murakami S, Matsuzaki O, Shimazaki J. Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 2001;8:(8) 431-436; discussion 437.
7. Moore SR, Reinberg Y, Zhang G. Small cell carcinoma of prostate: Effectiveness of hormonal versus chemotherapy. Urology 1992;39(5):411-416.
8. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinomaof prostatic origin. J Urol 1992;147(3 Pt 2):935-937.
9. Wynn SS, Nagabundi S, Koo J, Chin NW. Recurrent prostate carcinoma presenting as omental large cell carcinoma with neuroendocrine differentiation and resulting in bowel obstruction. Arch Pathol Lab Med 2000;124(7):1074-1076. (Pubitemid 30602052)
10. Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: A clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 2006;30(6):684-693. (Pubitemid 44264993)
11. Guo CC, Zuo G, Cao D, Troncoso P, Czerniak BA. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol 2009;22(7):866-871.
12. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4(2):249-264.
13. Pounds S, Morris SW. Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics 2003;19(10):1236-1242. (Pubitemid 36850216)
14. Zhang B, Schmoyer D, Kirov S, Snoddy J. GOTree Machine (GOTM): A web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies. BMC Bioinform 2004;5:16.
15. Vias M, Massie CE, East P, Scott H, Warren A, Zhou Z, Nikitin AY, Neal DE, Mills IG. Pro-neural transcription factors as cancer markers. BMC Med Genomics 2008;1:17.
16. Hu Y, Ippolito JE, Garabedian EM, Humphrey PA, Gordon JI. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 2002;277(46):44462-44474. (Pubitemid 36157881)
17. Rapa I, Ceppi P, Bollito E, Rosas R, Cappia S, Bacillo E, Porpiglia F, Berruti A, Papotti M, Volante M. Human ASH1 expression in prostate cancer with neuroendocrine differentiation. Mod Pathol 2008;21(6):700-707. (Pubitemid 351744835)
18. Foehr ED, Lorente G, Kuo J, Ram R, Nikolich K, Urfer R. Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res 2006;66(4):2271-2278.
19. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23(32): 8253-8261. (Pubitemid 46211563)
20. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: Locking up the molecular escape routes. Clin Cancer Res 2009;15(10):3251-3255.
21. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27(23):3742-3748.
22. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004;64(24):9209-9216. (Pubitemid 39665537)
23. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: A clinical, pathological and immunohistological study of 27 patients. J Urol 1992;147(3 Pt 2):804-807.
24. van Haaften-Day C, Raghavan D, Russell P, Wills EJ, Gregory P, Tilley W, Horsfall DJ. Xenografted small cell undifferentiated cancer of prostate: Possible common origin with prostatic adenocarcinoma. Prostate 1987;11(3):271-279. (Pubitemid 18004765)
25. Pinthus JH, Waks T, Schindler DG, Harmelin A, Said JW, Belldegrun A, Ramon J, Eshhar Z. WISH-PC2: A unique xenograft model of human prostatic small cell carcinoma. Cancer Res 2000;60(23):6563-6567.
26. True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, Macoska JA, Norwood T, Liu A, Ellis W, Lange P, Vessella R. A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am J Pathol 2002;161(2):705-715. (Pubitemid 36142179)
27. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, Chrousos G, Pass H, Doppman J. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15(6):529-553.
28. di Sant'Agnese PAEL, Epstein JI, Helpap B, Humphrey PA, Montironi R, Rubin MA, Sakr WA, Tan PH. Neuroendocrine tumors. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World health organization classification of tumors pathology and genetics of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer; (IARC); 2004. p 207.
29. Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S, Nakagawa K, Nomura H, Ishikawa Y., Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004;363(9411):775-781. (Pubitemid 38315167)
30. Hiroshima K, Iyoda A, Shida T, Shibuya K, Iizasa T, Kishi H, Tanizawa T, Fujisawa T, Nakatani Y. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: A morphological, immunohistochemical, and molecular analysis. Mod Pathol 2006;19(10):1358-1368. (Pubitemid 44423084)
31. Sun L, Sakurai S, Sano T, Hironaka M, Kawashima O, Nakajima T. High-grade neuroendocrine carcinoma of the lung: Comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma. Pathol Int 2009;59(8):522-529.
32. Adesina AM, Nguyen Y, Mehta V, Takei H, Stangeby P, Crabtree S, Chintagumpala M, Gumerlock MK. FOXG1 dysregulation is a frequent event in medulloblastoma. J Neurooncol 2007;85(2):111-122. (Pubitemid 47629393)
33. Adamson DC, Shi Q, Wortham M, Northcott PA, Di C, Duncan CG, Li J, McLendon RE, Bigner DD, Taylor MD, Yan H. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res 70(1):181-191.